Strain Improvement of Streptomyces xanthochromogenes RIA 1098 for Enhanced Pravastatin Production at High Compactin Concentrations
- 21 May 2015
- journal article
- Published by Springer Nature in Indian Journal of Microbiology
- Vol. 55 (4) , 440-446
Abstract
Pravastatin is one of the most popular cholesterol-lowering drugs. Its industrial production represents a two-stage process including the microbial production of compactin and its further biocatalytic conversion to pravastatin. To increase a conversion rate, a higher compactin content in fermentation medium should be used; however, high compactin concentrations inhibit microbial growth. Therefore, the improvement of the compactin resistance of a producer still remains a relevant problem. A multi-step random UV mutagenesis of a Streptomyces xanthochromogenes strain RIA 1098 and the further selection of high-yield compactin-resistant mutants have resulted in a highly productive compactin-resistant strain S 33-1. After the fermentation medium improvement, the maximum bioconversion rate of this strain has reached 91 % at the daily compactin dose equal to 1 g/L and still remained high (83 %) even at the doubled dose (2 g/L). A 1-year study of the mutant strain stability has proved a stable inheritance of its characteristics that provides this strain to be very promising for the pravastatin-producing industry.Keywords
This publication has 14 references indexed in Scilit:
- Pravastatin Sodium2014
- Statins: The paradigm shift in periodontal regenerationSRM Journal of Research in Dental Sciences, 2014
- Efficient bioconversion of compactin to pravastatin by the quinoline-degrading microorganism Pseudonocardia carboxydivorans isolated from petroleum-contaminated soilBioresource Technology, 2011
- Construction of a novel expression vector in Pseudonocardia autotrophica and its application to efficient biotransformation of compactin to pravastatin, a specific HMG-CoA reductase inhibitorBiochemical and Biophysical Research Communications, 2011
- Efficient Biotransformations UsingEscherichia coliwithtolCacrABMutations Expressing Cytochrome P450 GenesBioscience, Biotechnology, and Biochemistry, 2009
- Pravastatin: an evidence-based statin?Expert Opinion on Drug Metabolism & Toxicology, 2008
- Screening of Compactin-Resistant Microorganisms Capable of Converting Compactin to PravastatinCurrent Microbiology, 2006
- Bioconversion of compactin to pravastatin by Actinomadura sp. ATCC 55678Journal of Molecular Catalysis B: Enzymatic, 2000
- DNA sequencing with chain-terminating inhibitorsProceedings of the National Academy of Sciences, 1977
- ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.The Journal of Antibiotics, 1976